Home > Pulmonology > ERS 2020 > Asthma – What's New > First-in-class tyrosine kinase inhibitor shows promise in severe asthma

First-in-class tyrosine kinase inhibitor shows promise in severe asthma

Presented By
Prof. Pascal Chanez, Aix-Marseille Université, France
Conference
ERS 2020
A recent phase 3 study suggests that masitinib could be a novel treatment for patients with severe asthma as it demonstrated a positive benefit/risk ratio regardless of initial eosinophils level [1]. The multicentre, prospective, randomised, placebo-controlled phase 3 trial assessed masitinib 6 mg/kg/day in adult patients with severe asthma and insufficient disease control under oral corticosteroids (OCS) at >5 mg/day. The small molecule masitinib is a selective tyrosine kinase inhibitor that targets mast cell activity and exerts inhibition on platelet-derived growth factor receptor signalling associated with airway remodelling. The study included 355 participants for the primary analysis and 404 participants for the safety evaluation. They were randomised 2:1 to receive masitinib or placebo. All participants had a baseline FEV1 value ≥35% and <80% and at least 2 exacerba...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on